Q&A: Page 5

Exclusive interviews with industry leaders

  • Kinnari Patel Rocket Pharmaceuticals
    Image attribution tooltip
    Permission granted by Kinnari Patel Rocket Pharmaceuticals
    Image attribution tooltip

    Rocket Pharmaceuticals is ready for liftoff in the rare disease space

    With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.

    Taren Grom • Feb. 10, 2023
  • Victoria Richon
    Image attribution tooltip
    Permission granted by Entact Bio
    Image attribution tooltip

    Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

    Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

    Kelly Bilodeau • Feb. 6, 2023
  • Jill Milne Astria Therapeutics
    Image attribution tooltip
    Permission granted by Jill Milne, Astria Therapeutics
    Image attribution tooltip

    Astria Therapeutics’ edge in an ultra-rare disease

    With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

    Taren Grom • Feb. 1, 2023
  • Marc de Garidel, CEO, CinCor
    Image attribution tooltip
    Permission granted by CinCor
    Image attribution tooltip

    This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

    With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.

    Michael Gibney • Jan. 31, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    Meagan Parrish • Jan. 26, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Already on a roll in oncology, Astellas hunts for big wins in other areas

    With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

    Karissa Waddick • Jan. 23, 2023
  • Bekki Brown UBC
    Image attribution tooltip
    Permission granted by Bekki Brown
    Image attribution tooltip

    UBC crowns Bekki Brown as its new CEO with a clear mandate to grow

    The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.

    Taren Grom • Jan. 20, 2023
  • Sean McCarthy, CEO and chairman, CytomX
    Image attribution tooltip
    Permission granted by CytomX
    Image attribution tooltip

    A Moderna tie-up ushers in new era for CytomX

    The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

    Michael Gibney • Jan. 18, 2023
  • Hans Schambye Galecto
    Image attribution tooltip
    Permission granted by Hans Schambye
    Image attribution tooltip

    Galecto has identified a master switch to reduce fibroid formation

    With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

    Taren Grom • Jan. 11, 2023
  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

    The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

    Taren Grom • Jan. 9, 2023
  • A person in a white lab coat holds an Ipad and pen and sits across from someone gesturing with their hands.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    To drive trial diversity, one company is bringing them to the patient

    For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.

    Karissa Waddick • Dec. 21, 2022
  • arrow change
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career

    With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.

    Taren Grom • Dec. 9, 2022
  • Charlotte Owens, vice president, head of the Center for Health Equity and Patient Affairs, Takeda
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    Takeda’s global quest for health equity

    Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

    Taren Grom • Dec. 8, 2022
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    For Duchenne-focused Sarepta, gene therapy is the natural next step

    The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

    Michael Gibney • Dec. 8, 2022
  • Bill Mezzanotte headshot
    Image attribution tooltip
    Permission granted by CSL
    Image attribution tooltip

    A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

    The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

    Meagan Parrish • Dec. 6, 2022
  • Overhead view of a person holding two white pills in their left hand and a glass of water in their right hand.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Non-toxic and addiction free: The promise of a new pain med

    Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

    Taren Grom • Dec. 1, 2022
  • Skin
    Image attribution tooltip
    Ivan Balvan via Getty Images
    Image attribution tooltip

    Evommune’s unique method of drug discovery is more than skin deep

    The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

    Michael Gibney • Nov. 29, 2022
  • lab tubes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    In cancers with very low survival rates, Sellas aims higher

    The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

    Kelly Bilodeau • Nov. 21, 2022
  • Glen de Vries blue origin
    Image attribution tooltip
    Permission granted by Medidata
    Image attribution tooltip

    The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

    Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

    Taren Grom • Nov. 11, 2022
  • Lene Oddershede
    Image attribution tooltip
    Permission granted by Lene Oddershede
    Image attribution tooltip

    Novo Nordisk’s quantum bet on ‘world changing’ computing

    Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

    Taren Grom • Nov. 10, 2022
  • Disabilities
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The other ‘D’ in DE&I

    How companies can work to include people with disabilities into broader equity aims.

    Taren Grom • Nov. 4, 2022
  • tuberculosis scan
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that

    The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.

    Alexandra Pecci • Nov. 1, 2022
  • Two researchers pipette blue liquid from beaker's to test tubes.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

    Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

    Karissa Waddick • Oct. 27, 2022
  • Wearing a black hoodie, Carolyn Bertozzi stands in the forefront with a tan brick building blurred behind.
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images
    Image attribution tooltip

    Nobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development

    The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.

    Karissa Waddick • Oct. 26, 2022
  • Ryan Moslin, senior principal scientist, Bristol Myers Squibb
    Image attribution tooltip
    Permission granted by BMS / Ryan Moslin
    Image attribution tooltip

    He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

    Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

    Michael Gibney • Oct. 17, 2022